瑞士Oculis公司报告说,对急性光纤神经炎进行新治疗的试验结果很成功。 Swiss company Oculis reports successful trial results for a new treatment for acute optic neuritis.

瑞士一家生物制药公司Oculis报告了OSCS-05的第二阶段试验成功结果,Oculis是治疗急性眼神经炎的治疗。 Oculis, a Swiss biopharmaceutical company, has reported successful Phase 2 trial results for OCS-05, a treatment for acute optic neuritis. 试验显示,视觉和视网膜措施有重大改进,达到了安全和效能目标。 The trial showed significant improvements in visual and retinal measures, meeting safety and efficacy goals. 这一成功使公司能够继续美国临床发展,并考虑将治疗扩大到其他神经退化性疾病。 This success allows the company to proceed with U.S. clinical development and consider expanding the therapy to other neurodegenerative diseases.